The effectiveness of sodium-glucose co-transporter 2 inhibitors (SGLT2i) highlights the importance of well-powered clinical trials that have identified a new treatment strategy for type 2 diabetes, according to a state-of-the-art review published July 31 in the Journal of the American College of Cardiology.

Thomas A. Zelniker, MD, MSc, and Eugene Braunwald, MD, MACC, review the cardiovascular outcome trials for SGLT2is and their clinical implications. "The favorable effects of SGLT2i ... represent an unexpected bonus of the FDA's advisory in 2008 to test new glucose agents for cardiovascular safety in large post-marketing trials," the authors write. Read more on ACC.org.

Check out the College’s diabetes resources including the Diabetes Collaborative Registry, the Succeed in Managing Cardiovascular Risk in Diabetes Initiative, ACC’s free online educational activity on “Lifting the Burden of Cardiovascular Disease and Diabetes,” and CardioSmart patient resources.

Find all of these resources and more on the Diabetes and Cardiometabolic Disease Clinical Topic Collection on ACC.org.